AXSM - Axsome Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
77.38
+2.90 (+3.89%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close74.48
Open74.70
Bid74.80 x 900
Ask79.00 x 1800
Day's range72.27 - 78.82
52-week range13.64 - 109.94
Volume584,608
Avg. volume973,062
Market cap2.869B
Beta (5Y monthly)3.27
PE ratio (TTM)N/A
EPS (TTM)-1.62
Earnings date06 Aug 2020 - 10 Aug 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est162.50
  • GlobeNewswire

    Axsome Therapeutics to Present at Upcoming Investor Conferences

    Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a virtual fireside chat. A live webcast and archive of the William Blair event can be viewed on the "Webcasts & Presentations" page of the "Investors" section of the Company's website at www.axsome.com. Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options.

  • GlobeNewswire

    Axsome Therapeutics Presents Data from GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder at the 2020 American Society for Clinical Psychopharmacology Annual Meeting

    Axsome Therapeutics, Inc. (AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that data from the GEMINI Phase 3 trial of AXS-05 in major depressive disorder (MDD) will be presented in oral and poster sessions at the 2020 Annual Meeting of the American Society for Clinical Psychopharmacology (ASCP), to be held virtually, May 29-30. AXS-05 (dextromethorphan/bupropion modulated delivery tablet) is a novel, oral, investigational NMDA receptor antagonist with multimodal activity.

  • Is Axsome Therapeutics a Buy?
    Motley Fool

    Is Axsome Therapeutics a Buy?

    The pharmaceutical company appears poised to earn multiple regulatory approvals in 2021. But has too much anticipated success already been priced into its shares?

  • GlobeNewswire

    Axsome Therapeutics to Host 2020 Annual Meeting of Stockholders Virtually

    Axsome Therapeutics, Inc. (AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the Company’s 2020 Annual Meeting of Stockholders will now be held in a virtual-only meeting format due to continued public health concerns resulting from the COVID-19 pandemic, government-recommended and required limits on public gatherings, and to protect the health and safety of the Company’s stockholders, directors, and employees. Stockholders will not be able to attend the Annual Meeting in person. The Company’s stockholders as of the close of business on April 9, 2020 (the “Record Date”) can join the live virtual meeting.

  • Better Buy: Biogen vs. Axsome Therapeutics
    Motley Fool

    Better Buy: Biogen vs. Axsome Therapeutics

    One biotech has been big long-time winner, the other is a promising up-and-comer with no revenue -- yet. But picking an investment is always a bet on the future.

  • What's Behind Axsome Therapeutics' Miracle Pipeline?
    Motley Fool

    What's Behind Axsome Therapeutics' Miracle Pipeline?

    Just what exactly is going on with this company, which has had success in nearly every single clinical trial it initiated in recent years?

  • Axsome's (AXSM) Earnings Miss in Q1, Pipeline Progresses
    Zacks

    Axsome's (AXSM) Earnings Miss in Q1, Pipeline Progresses

    Axsome (AXSM) incurs a wider loss in the first quarter of 2020. However, the company is advancing well with the NDA for AXS-05 and AXS-07.

  • Axsome Therapeutics, Inc. (AXSM) Q1 2020 Earnings Call Transcript
    Motley Fool

    Axsome Therapeutics, Inc. (AXSM) Q1 2020 Earnings Call Transcript

    During today's call, we will be making certain forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are only made as of today's date, and the company disclaims any obligation to update such statements.

  • Why Jazz Pharmaceuticals' Symphony of Growth Is About to End
    Motley Fool

    Why Jazz Pharmaceuticals' Symphony of Growth Is About to End

    Competition is about to ramp up significantly in the $1.7 billion market for treating chronic sleep disorder.

  • Is Axsome Therapeutics a Screaming Buy?
    Motley Fool

    Is Axsome Therapeutics a Screaming Buy?

    The past few weeks have been quite busy for Axsome Therapeutics (NASDAQ: AXSM), notching two wins and one failure in late-stage clinical trials. On March 30, the company reported its drug AXS-05 failed to achieve the primary endpoint in a phase 3 clinical trial for patients with treatment-resistant depression. Weeks later, Axsome hailed a clinical trial success with AXS-05 for Alzheimer's disease-related agitation.

  • GlobeNewswire

    Axsome Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update

    Clinical successes highlight Axsome’s accelerated evolution into a leading CNS company Positive pivotal Phase 2/3 results for AXS-05 in Alzheimer’s disease agitation further.

  • Here's Why Axsome Therapeutics Rocketed 61.5% Higher in April
    Motley Fool

    Here's Why Axsome Therapeutics Rocketed 61.5% Higher in April

    Shares of Axsome Therapeutics (NASDAQ: AXSM), a clinical-stage biopharmaceutical company, rocketed 61.5% in April, according to data from S&P Global Market Intelligence. March was a rough month for Axsome Therapeutics shareholders. Investors that held on to their shares were made whole by the end of April thanks to a couple of positive data drops.

  • There May Be a New First-Line Treatment for Depression
    Motley Fool

    There May Be a New First-Line Treatment for Depression

    Key details in an antidepressant's clinical trial may signal a revolutionary therapy for patients.

  • GlobeNewswire

    Axsome Therapeutics to Report First Quarter 2020 Financial Results on May 8, 2020

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter of 2020 on Friday, May 8, 2020 before the opening of the U.S. financial markets. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements.

  • GlobeNewswire

    Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ADVANCE-1 Pivotal Phase 2/3 Trial in Alzheimer’s Disease Agitation

    Statistically significant improvement in Alzheimer’s disease agitation, as measured by the CMAI total score compared to placebo (p=0.010, primary endpoint) Demonstrated rapid.

  • GlobeNewswire

    Axsome Therapeutics Announces AXS-07 Achieves Both Co-Primary Endpoints and Prevents Migraine Pain Progression in the INTERCEPT Phase 3 Trial in the Early Treatment of Migraine

    Achieved freedom from migraine pain in 33% of AXS-07 patients versus 16% for placebo at 2 hours (co-primary endpoint, p=0.002) Prevented progression of migraine pain beyond.

  • GlobeNewswire

    Axsome Therapeutics Announces Topline Results of the STRIDE-1 Phase 3 Trial in Treatment Resistant Depression and Expert Call to Discuss Clinical Implications

    Achieves key secondary endpoints demonstrating rapid and statistically significant improvements in depressive symptoms on MADRS versus active comparator at Weeks 1, 2, and.

  • GlobeNewswire

    Axsome Therapeutics Accelerates Completion of the ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it is accelerating the completion of the ADVANCE-1 Phase 2/3 trial of AXS-05 in patients with Alzheimer’s disease (AD) agitation to ensure the safety of this vulnerable patient population during the COVID-19 pandemic, while maintaining the integrity of the clinical trial. AXS-05 (dextromethorphan/bupropion modulated delivery tablet) is a novel, oral, investigational NMDA receptor antagonist with multimodal activity. The decision to accelerate the completion of this trial was made in light of the newly issued U.S. Food and Drug Administration (FDA) Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic, which discusses the potential impact of the pandemic on the conduct of clinical trials and on the resulting need to ensure the safety of trial participants.

  • GlobeNewswire

    Axsome Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

    NDA filing for Breakthrough Therapy designated AXS-05 in MDD expected in 4Q 2020 NDA filing for AXS-07 in migraine expected in 4Q 2020 Topline results for STRIDE-1 Phase 3.

  • GlobeNewswire

    Axsome Therapeutics Announces the Promotion of Mark Jacobson to Chief Operating Officer

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the appointment of Mark Jacobson as Chief Operating Officer. In this new role, Mr. Jacobson will oversee the day-to-day operations of the company, including aspects of research and development, manufacturing, program management, and corporate development. “I am delighted to announce the promotion of Mark which recognizes his exceptional leadership and results-oriented approach, making him the ideal person to lead operations for Axsome through what we believe to be a transformational time,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome.

  • GlobeNewswire

    Axsome Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for fiscal year 2019 on Thursday, March 12, 2020 before the opening of the U.S. financial markets. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements.

  • GlobeNewswire

    Axsome Therapeutics Completes Patient Enrollment in the INTERCEPT Phase 3 Trial of AXS-07 in the Early Treatment of Migraine

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the completion of patient enrollment in the INTERCEPT study, a Phase 3, randomized, double-blind, placebo-controlled trial evaluating the early treatment of migraine with AXS-07. AXS-07 (MoSEIC™ meloxicam/rizatriptan) is a novel, oral, investigational medicine with distinct dual mechanisms of action for the acute treatment of migraine.

  • Axsome Therapeutics (AXSM) Gains But Lags Market: What You Should Know
    Zacks

    Axsome Therapeutics (AXSM) Gains But Lags Market: What You Should Know

    Axsome Therapeutics (AXSM) closed at $87.60 in the latest trading session, marking a +0.72% move from the prior day.

  • Axsome (AXSM) Completes Patient Randomization in TRD Study
    Zacks

    Axsome (AXSM) Completes Patient Randomization in TRD Study

    Axsome (AXSM) closes patient randomization in the late-stage study of AXS-05 for addressing patients with treatment resistant depression.

  • GlobeNewswire

    Axsome Therapeutics Completes Patient Randomization in the STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the completion of patient randomization in the STRIDE-1 study, a Phase 3, randomized, double-blind, active-controlled trial of AXS-05 in patients with treatment resistant depression (TRD). AXS-05 (dextromethorphan/bupropion modulated delivery tablet) is a novel, oral, investigational NMDA receptor antagonist with multimodal activity. STRIDE-1 (Symptom Treatment in Resistant Depression 1) is a Phase 3, randomized, double-blind, active controlled trial to assess the efficacy and safety of AXS-05 in the treatment of treatment resistant depression (TRD).